Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) Invested Capital (2022 - 2025)

Stoke Therapeutics has reported Invested Capital over the past 4 years, most recently at $352.5 million for Q4 2025.

  • Quarterly results put Invested Capital at $352.5 million for Q4 2025, up 53.9% from a year ago — trailing twelve months through Dec 2025 was $352.5 million (up 53.9% YoY), and the annual figure for FY2025 was $352.5 million, up 53.9%.
  • Invested Capital for Q4 2025 was $352.5 million at Stoke Therapeutics, up from $308.1 million in the prior quarter.
  • Over the last five years, Invested Capital for STOK hit a ceiling of $352.5 million in Q4 2025 and a floor of $140.3 million in Q1 2024.
  • Median Invested Capital over the past 4 years was $226.7 million (2022), compared with a mean of $236.2 million.
  • Biggest five-year swings in Invested Capital: plummeted 34.37% in 2024 and later soared 149.44% in 2025.
  • Stoke Therapeutics' Invested Capital stood at $184.8 million in 2022, then decreased by 13.68% to $159.6 million in 2023, then soared by 43.53% to $229.0 million in 2024, then soared by 53.9% to $352.5 million in 2025.
  • The last three reported values for Invested Capital were $352.5 million (Q4 2025), $308.1 million (Q3 2025), and $334.9 million (Q2 2025) per Business Quant data.